Ebola vaccine gold rush: Tekmira investors need a full-blown pandemic to really cash in
by Mike Adams
NaturalNews.com
Monday, August 11, 2014
How do you make money from a deadly pandemic? According to tens of thousands of investors, you plow money into Tekmira Pharmaceuticals, the company that’s suddenly the darling of the pharmaceutical industry due to its early R&D work on an Ebola vaccine.
The company’s Ebola vaccine trial was on hold by the FDA, but after a calculated petition was posted last week urging the FDA to allow the trial to move forward, the FDA reversed its position and announced a fast-track approval for human trials. Tekmira’s stock price skyrocketed nearly 100% and now stands at around $26 per share. (Since when did an online petition ever get the FDA to move on anything other than pharmaceutical profits?)
Over 28 million shares of Tekmira stock changed hands last Friday in a flurry of buying activity. But have all these investors really thought about what would be necessary for Tekmira to earn a profit on its research?
Essentially, Tekmira only becomes profitable if there’s an exploding Ebola pandemic that begins killing people en masse, thereby forcing world governments to purchase and stockpile the vaccine.
The gold rush has already begun. Here’s a five-day chart of Tekmira’s share price. The huge upticks correspond with the FDA clearing the company for Ebola vaccine trials:
The Rest…HERE
